FDA Approves C5 siRNA for AChR Positive Myasthenia

Company Regeneron (siRNA platform licensed from Alnylam) Event Type FDA approval (prior-evening release recovered) Modality siRNA Asset Cemdisiran (Livsayis) Target Complement C5 mRNA Disease Area Anti-AChR-positive generalized myasthenia gravis Summary FDA approved cemdisiran, Livsayis, for adults with anti-AChR-positive generalized myasthenia gravis on November 18. The…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *